aberrations in cancer cells and targeted therapies shermaine mitchell july 27 2011 phd candidate

25
Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Upload: barnaby-potter

Post on 18-Dec-2015

214 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Aberrations in Cancer Cells and Targeted Therapies

Shermaine Mitchell

July 27 2011

PhD Candidate

Page 2: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Targeted therapy

Standard Chemo-therapy

Patient

Page 3: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Normal cells vs. Cancer cells

Page 4: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Cancer…what is it?

Uncontrolled growth of abnormal cells in the body

Benign and or pre-malignant tumors

ARE NOT CANCER A disease of the genome: Cancer is a

genetic disease1. Gain of function mutation

2. Loss of function mutations

3. Gene amplification

4. Overexpression

Page 6: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Intracellular signaling

Page 8: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Targeted Therapy

Page 9: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate
Page 10: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Growth factor signaling

Page 11: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Overexpression of receptor

Page 12: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Herceptin

Page 13: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Mutations in Effector Molecules

Page 14: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Lipidmodification for function

Page 15: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate
Page 16: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Loss of function mutation: evading apoptosis

Page 17: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate
Page 18: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Onyx -015

Page 19: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Old Dog with New Tricks

Page 20: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Ovarian Cancer

Most lethal gynecological cancer

65% of patients are diagnosed with stage III or stage IV disease

Recurring and resistant to treatment

21,880 new cases 13,850 deaths 85-90% of ovarian

cancers overexpress FRα20

No

rmal

Sta

ge

I

Sta

ge

II

Sta

ge

III

Sta

ge

IV

0.00001

0.0001

0.001

0.01

0.1

1

Rel

ativ

e F

R a

lph

a T

ran

scri

pts

Courtesy of Christina Cherian

Ovarian Cancer

Page 21: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Mechanisms of Intracellular Folate Transport

21

• Predominant transporter of (anti)folates

Zhao R, Matherly LH, Goldman ID: Expert Rev. Mol. Med., 2009

PCFT=Proton-coupled folate transporterRFC=Reduced folate carrier

Page 22: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Folates Essential water soluble B

vitamin Amino acid synthesis Essential for DNA

synthesis

a. Thymidylate (dTMP):TS

b. Purine nucleotides :

GARFT + AICARFT

Antifolates

Structural analogs of folic acid

Disrupt DNA synthesis Recognized by cellular

machinery used by folates

a. receptors

b. intracellular targets Inhibition of folate

dependent enzymes Nucleotide depletion

22

GARFT=Glycinamine Ribonucleotide formyl transferaseAICARFT= 5-Aminoimidozole 4-carboxamide ribonucleotide formyl transferaseTS= Thymidylate Synthase

Page 23: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Normal vs. Cancer cells

Blood LumenBloodLumen

Normal Solid Tumors

RFC

vv

PCFT FRα23

Page 24: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Antifolates

Aminopterin MTX Pemetrexed…

Page 25: Aberrations in Cancer Cells and Targeted Therapies Shermaine Mitchell July 27 2011 PhD Candidate

Questions????